surmount-1 trial tirzepatide weight loss results reduction with different doses of in Surmount 1 SURMOUNT-1: Tirzepatide Drastically Reduces Weight

There is no established pharmacological mechanism by which semaglutide would directly cause stool discolouration

Further research is needed, however, to examine the psychological effects of exposing people who are overweight and obese to images that emphasize their body size and shape

The future of the GLP-1 drug market is driven by key trends, including patent expirations, manufacturing challenges, and advancements in drug delivery

Diabetologia 67 , 470482 (2024)

Insurers such as United Healthcare, Cigna, and Blue Cross Blue Shield may cover semaglutide, often contingent on a prior authorization, while Medicare and Medicaid coverage might differ by state

Early functional insights linked these structures to paracellular transport regulation